molmed

News & Events

Stay update

42nd Annual Meeting of the European Society for Blood and Marrow Transplantation-EBMT 2016 ▾

42nd Annual Meeting of the European Society for Blood and Marrow Transplantation-EBMT 2016

Location: Valencia, Spain

MolMed at this event: MolMed Satellite Symposium, title: Pioneering hematopoietic cell engineering - April 5th, time: 13:45-15:15, Auditorium 3A

Investors

MolMed and Takara Bio agreed on terminating the license agreement on TK therapy in Asia countries.

MolMed and Takara Bio agreed on terminating the license agreement on TK therapy in Asia countries. ▾

Investors

No list received at expiry of the extended deadline for submitting lists for the board of statutory auditors

No list received at expiry of the extended deadline for submitting lists for the board of statutory auditors ▾

Investors

Financial calendar for fiscal year 2016

Financial calendar for fiscal year 2016 ▾

Investors

Lists of candidates for corporate bodies and prorogation for statutory auditors' lists

Lists of candidates for corporate bodies and prorogation for statutory auditors' lists ▾

Investors

MolMed and Genenta Science sign a collaboration agreement in the field of gene therapy for the treatment of tumors

MolMed and Genenta Science sign a collaboration agreement in the field of gene therapy for the treatment of tumors ▾

Investors

MolMed’s Board of Directors approved the 2015 draft financial statements and convened the shareholders’ meeting

MolMed’s Board of Directors approved the 2015 draft financial statements and convened the shareholders’ meeting ▾

News & Events

Stay update

MolMed: Riccardo Palmisano appointed President of Assobiotec ▾

MolMed: Riccardo Palmisano appointed President of Assobiotec

Location: Roma

Investors

MolMed: organizational structure optimization and further corporate governance strengthening Pdf

MolMed: organizational structure optimization and further corporate governance strengthening Pdf ▾

Investors

Annual financial report 2015

Annual financial report 2015 ▾

Subscribe to

Subscribe to press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.